Ampyra (fampridine-SR) was FDA approved for all forms of MS on January 22. A time-release pill that improves walking, it is the first oral MS drug and the first specifically approved to control an MS symptom. But there’s more to know. The Society has developed a comprehensive FAQ and a webcast.
Oral MS disease-modifying drugs could become available by next year. Promising results from two front-runners were published online in the New England Journal of Medicine on January 20. Read more about them:
Get updates on Society action to spur exploration of CCSVI. On Feb. 9, Dr. Patricia O'Looney (right) of the Society’s research staff met with Dr. Zamboni (left) and Dr. Herbert at an NYU briefing.
We’re going on a 10-week, cross-country journey to share the stories of people affected by MS and how they keep moving. Don’t miss this opportunity to have your story told. This initiative is supported in part by Novartis Pharmaceuticals Corporation. At right, the video team.
MS stops people from moving. The National MS Society exists to make sure it doesn’t. We are a collective of passionate individuals, moving together to create a world free of MS. JOIN THE MOVEMENT?
Please do not reply to this email as we are unable to quickly respond to messages sent to this address. To receive information about living with MS, Bike MS or Walk MS — or to contact National MS Society staff in your area — please visit our Web site.
Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.
National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017
This message was sent to . To ensure that you continue to receive our emails, please add us to your address book.